Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
bioAffinity Technologies, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/26/2023 |
3
| Joyce Roby (Director) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 08/11/2023 |
4
| GIRGENTI STEVEN (Executive Chairman) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Granted 8,227 shares
@ $2.28, valued at
$18.8k
Granted 9,920 shares
@ $1.89, valued at
$18.7k
Granted 10,245 shares
@ $1.83, valued at
$18.7k
Granted 26,315 shares
@ $2.28, valued at
$60k
|
|
| 07/06/2023 |
4
| GIRGENTI STEVEN (Executive Chairman) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Granted 8,227 shares
@ $2.28, valued at
$18.8k
Granted 9,920 shares
@ $1.89, valued at
$18.7k
Granted 10,245 shares
@ $1.83, valued at
$18.7k
|
|
| 07/06/2023 |
4
| Rubin Gary D (10% Owner) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Granted 8,227 shares
@ $2.28, valued at
$18.8k
Granted 9,920 shares
@ $1.89, valued at
$18.7k
Granted 10,245 shares
@ $1.83, valued at
$18.7k
|
|
| 07/06/2023 |
4
| Zannes Maria (President, CEO) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Granted 8,227 shares
@ $2.28, valued at
$18.8k
Granted 9,920 shares
@ $1.89, valued at
$18.7k
Granted 26,178 shares
@ $1.91, valued at
$50k
Granted 10,245 shares
@ $1.83, valued at
$18.7k
|
|
| 07/06/2023 |
4
| KNIGHT PETER S (Director) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Granted 8,227 shares
@ $2.28, valued at
$18.8k
Granted 9,920 shares
@ $1.89, valued at
$18.7k
Granted 10,245 shares
@ $1.83, valued at
$18.7k
|
|
| 07/06/2023 |
4
| Dougherty Michael Philip (CFO) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Granted 52,356 shares
@ $1.91, valued at
$100k
|
|
| 05/11/2023 |
3
| Dougherty Michael Philip (CFO) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 03/07/2023 |
4
| Perlmutter Nathan M (10% Owner) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Converted 31,780 shares
@ $4.2, valued at
$133.5k
Converted 87,851 shares
@ $4.2, valued at
$369k
Converted 27,378 shares
@ $4.2, valued at
$115k
Converted 14,811 shares
@ $6.75, valued at
$100k
Converted options to buy
@ $0
Converted 103,682 options to buy
@ $0
Granted 24,602 options to buy
@ $0
Granted 71,428 options to buy
@ $0
Granted 23,809 options to buy
@ $0
Granted 47,935 options to buy
@ $5.25, valued at
$251.7k
|
|
| 03/07/2023 |
3
| Perlmutter Nathan M (10% Owner) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 03/07/2023 |
4
| Meghji Mohsin Y (Director) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Converted 40,907 shares
@ $3.67, valued at
$150.1k
Converted 286,349 options to buy
@ $0 |
|
| 03/07/2023 |
3
| Meghji Mohsin Y (Director) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 12/05/2022 |
4
| Zannes Timothy P (Secretary, EVP, Gen. Counsel) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Granted 3,619 shares
@ $0 |
|
| 12/05/2022 |
3
| Zannes Timothy P (Secretary, EVP, Gen. Counsel) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 12/05/2022 |
4
| KNIGHT PETER S (Director) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Bought 8,163 shares
@ $0
Bought 8,163 options to buy
@ $0 |
|
| 12/05/2022 |
3
| KNIGHT PETER S (Director) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 12/02/2022 |
4
| Anderson Robert A. (Director) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Bought 4,081 shares
@ $0
Bought 4,081 options to buy
@ $0 |
|
| 12/02/2022 |
3
| Anderson Robert A. (Director) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 12/02/2022 |
4
| DIAMOND STUART (Director) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Bought 4,081 shares
@ $0
Bought 4,081 options to buy
@ $0 |
|
| 12/02/2022 |
3
| DIAMOND STUART (Director) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 11/29/2022 |
4
| Edwards James Michael (CFO) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Bought 2,448 shares
@ $0
Converted 2,243 shares
@ $4.2, valued at
$9.4k
Granted 3,619 shares
@ $0
Bought 2,448 options to buy
@ $0
Converted options to buy
@ $0
Granted 1,903 options to buy
@ $0
Granted 761 options to buy
@ $5.25, valued at
$4k
|
|
| 11/29/2022 |
3
| Edwards James Michael (CFO) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 11/22/2022 |
4
| Rebel Vivienne I (EVP, Chief Sci. & Med. Officer) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Granted 7,239 shares
@ $0 |
|
| 11/22/2022 |
3
| Rebel Vivienne I (EVP, Chief Sci. & Med. Officer) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 11/22/2022 |
4
| Zannes Maria (President, CEO) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Bought 16,326 shares
@ $0
Converted 23,672 shares
@ $4.2, valued at
$99.4k
Granted 18,099 shares
@ $0
Bought 16,326 options to buy
@ $0
Converted options to buy
@ $0
Granted 23,571 options to buy
@ $0 |
|
| 11/22/2022 |
3
| Zannes Maria (President, CEO) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 11/08/2022 |
4
| GIRGENTI STEVEN (Executive Chairman) has filed a Form 4 on bioAffinity Technologies, Inc.|
Txns:
| Converted 7,657 shares
@ $4.2, valued at
$32.2k
Converted 156,602 shares
@ $4.2, valued at
$657.7k
Converted 7,657 shares
@ $4.2, valued at
$32.2k
Converted 59,141 shares
@ $4.2, valued at
$248.4k
Converted 58,797 shares
@ $4.2, valued at
$246.9k
Converted 27,378 shares
@ $4.2, valued at
$115k
Converted 4,912 shares
@ $4.2, valued at
$20.6k
Converted 2,694 shares
@ $4.2, valued at
$11.3k
Converted 13,326 shares
@ $4.2, valued at
$56k
Converted 10,632 shares
@ $4.2, valued at
$44.7k
Converted 39,275 shares
@ $4.2, valued at
$165k
|
|
| 11/08/2022 |
3
| GIRGENTI STEVEN (Executive Chairman) has filed a Form 3 on bioAffinity Technologies, Inc. |
| 10/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/21/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|
|